Related references
Note: Only part of the references are listed.Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults
Aaron M. Cook et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacometrics-Based Dose Selection of Levofloxacin as a Treatment for Postexposure Inhalational Anthrax in Children
Fang Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Levofloxacin in the treatment of community-acquired pneumonia
Ayman M. Noreddin et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study
C. R. Frei et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China
Ying-yuan Zhang et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2009)
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China
Jing Zhang et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2009)
Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia
Howard Friedman et al.
VALUE IN HEALTH (2009)
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay
Jeff Schein et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Levofloxacin - A review of its use as a high-dose, short-course treatment for bacterial infection
Vanessa R. Anderson et al.
DRUGS (2008)
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli:: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model
Inga Odenholt et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury
Tyree H. Kiser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation
CR Frei et al.
PHARMACOTHERAPY (2005)
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects
KA Sprandel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults
KA Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the antimicrobial resistance rate epidemiology study team
RN Jones et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers
AT Chow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae
MB Kays et al.
PHARMACOTHERAPY (2000)
Share Paper
